Vertex Pharmaceuticals Incorporated  

(Public, NASDAQ:VRTX)   Watch this stock  
Find more results for vrtx
+1.57 (1.21%)
Real-time:   9:41AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 129.59 - 131.21
52 week 97.45 - 143.45
Open 131.00
Vol / Avg. 4.00/1.68M
Mkt cap 33.09B
P/E     -
Div/yield     -
EPS -2.75
Shares 245.72M
Beta 0.51
Inst. own 97%
Jan 26, 2016
Q4 2015 Vertex Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 1, 2015
Vertex Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - 11:00AM EST - Add to calendar
Nov 10, 2015
Vertex Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Oct 28, 2015
Q3 2015 Vertex Pharmaceuticals Inc Earnings Call
Oct 28, 2015
Q3 2015 Vertex Pharmaceuticals Inc Earnings Release
Oct 9, 2015
Vertex Pharmaceuticals Inc at NACFC
Sep 16, 2015
Vertex Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -30.28% -127.81%
Operating margin -22.60% -112.97%
EBITD margin - -99.62%
Return on average assets -15.65% -31.88%
Return on average equity -42.01% -60.68%
Employees 1,830 -
CDP Score - -


50 Northern Ave
BOSTON, MA 02210-1862
United States - Map
+1-617-3416393 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertex’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Company’s product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Company’s product KALYDECO is available in the market.

Officers and directors

Jeffrey M. Leiden M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Ian F. Smith CPA Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
David Altshuler M.D., Ph.D. Executive Vice President - Global Research, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Stuart A. Arbuckle Executive Vice President, Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Jeffrey A. Chodakewitz M.D. Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Amit K. Sachdev J.D. Executive Vice President - Global Government Strategy, Market Access and Value
Age: 47
Bio & Compensation  - Reuters
Paul M. Silva Senior Vice President, Corporate Controller
Age: 48
Bio & Compensation  - Reuters
Bruce I. Sachs Co-Lead Independent Director
Age: 55
Bio & Compensation  - Reuters
Elaine S. Ullian Co-Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Joshua S. Boger Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters